Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data

Parkinson, 2012, Considerations in the development of circulating tumor cell technology for clinical use, J Transl Med, 10, 138, 10.1186/1479-5876-10-138 Cristofanilli, 2004, Circulating tumor cells, disease progression, and survival in metastatic breast cancer, N Engl J Med, 351, 781, 10.1056/NEJMoa040766 Cristofanilli, 2005, Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer, J Clin Oncol, 23, 1420, 10.1200/JCO.2005.08.140 Nolé, 2008, Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications, Ann Oncol, 19, 891, 10.1093/annonc/mdm558 Liu, 2009, Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer, J Clin Oncol, 27, 5153, 10.1200/JCO.2008.20.6664 Bidard, 2010, Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy, Ann Oncol, 21, 1765, 10.1093/annonc/mdq052 Nakamura, 2010, Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer, Breast Cancer, 17, 199, 10.1007/s12282-009-0139-3 Consoli, 2011, Circulating tumor cells as predictors of prognosis in metastatic breast cancer: clinical application outside a clinical trial, Tumori, 97, 737, 10.1177/030089161109700610 Hartkopf, 2011, Changing levels of circulating tumor cells in monitoring chemotherapy response in patients with metastatic breast cancer, Anticancer Res, 31, 979 Pierga, 2012, High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients, Ann Oncol, 23, 618, 10.1093/annonc/mdr263 Müller, 2012, Prognostic impact of circulating tumor cells assessed with the CellSearch System and AdnaTest Breast in metastatic breast cancer patients: the DETECT study, Breast Cancer Res, 14, R118, 10.1186/bcr3243 Martín, 2013, Circulating tumor cells following first chemotherapy cycle: an early and strong predictor of outcome in patients with metastatic breast cancer, Oncologist, 18, 917, 10.1634/theoncologist.2012-0479 Pierga, 2013, Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial, Ann Oncol, 24, 2999, 10.1093/annonc/mdt348 Bidard, 2012, Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study, Breast Cancer Res, 14, R29, 10.1186/bcr3114 Allard, 2004, Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases, Clin Cancer Res, 10, 6897, 10.1158/1078-0432.CCR-04-0378 Cuzick, 2011, Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer, J Clin Oncol, 29, 4273, 10.1200/JCO.2010.31.2835 Harrell, 1996, Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors, Stat Med, 15, 361, 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4 Anderson, 1983, Analysis of survival by tumor response, J Clin Oncol, 1, 710, 10.1200/JCO.1983.1.11.710 Giordano, 2012, Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy, Ann Oncol, 23, 1144, 10.1093/annonc/mdr434 Bidard, 2013, Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials, Cancer Metastasis Rev, 32, 179, 10.1007/s10555-012-9398-0 Smerage JB, Barlow WE, Hayes DF, et al. SWOG S0500—A randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell (CTC) levels at first follow-up assessment. 2013 San Antonio Breast Cancer Symposium, Dec 10–14, 2013. S5-07. Lin, 2013, International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer, Breast, 22, 203, 10.1016/j.breast.2013.03.006 Dawson, 2013, Analysis of circulating tumor DNA to monitor metastatic breast cancer, N Engl J Med, 368, 1199, 10.1056/NEJMoa1213261 Bidard, 2013, Going with the flow: from circulating tumor cells to DNA, Sci Transl Med, 5, 207ps14, 10.1126/scitranslmed.3006305 Febbo, 2011, NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology, J Natl Compr Canc Netw, 9, S1, 10.6004/jnccn.2011.0137 Yu, 2013, Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition, Science, 339, 580, 10.1126/science.1228522 Pailler, 2013, Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer, J Clin Oncol, 31, 2273, 10.1200/JCO.2012.44.5932 Heitzer, 2013, Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing, Cancer Res, 73, 2965, 10.1158/0008-5472.CAN-12-4140